Chrysos Corporation has secured a master services agreement (MSA) with Newmont for the adoption of its PhotonAssay technology in the latter’s gold mining operations. This technology is expected to transform gold, silver, copper and other elemental analysis with its rapid and environmentally friendly approach. By exposing samples to high-energy X-rays, Chrysos PhotonAssay technology excites atomic nuclei, enabling improved analysis of gold, silver, copper and other elements in as little as two minutes. It offers a substantial improvement over conventional assays with reduced labour and operating costs, enhanced accuracy and precision, and improved occupational health and safety, according to the company. An initial PhotonAssay unit is due to be installed at Newmont's Ahafo mine along the Sefwi Volcanic Belt in Ghana in the first half of fiscal year 2026 (FY26). The agreement between Chrysos and Newmont is structured around the general terms Chrysos offers, featuring an optional renewable five-year term, a fee per sample analysed and a stipulated minimum monthly assay payment. Chrysos managing director and CEO Dirk Treasure said: “We are proud to have secured both a Master Services Agreement and an initial lease contract with the industry’s leading gold miner. It is a testament not only to Newmont’s approach to operational and environmental excellence, but also reinforcing the significance of PhotonAssay itself. “We are continuing our strategy of converting the world’s biggest gold miners to PhotonAssay. We are pleased to see top and mid-tier producers adopting our technology at their projects, a trend that will only accelerate as we continue to penetrate the global mining market.” In April this year, Newmont concluded the $4.3bn sale of its Akyem and Porcupine operations in Ghana and Canada. "Chrysos signs first PhotonAssay unit contract with Newmont" was originally created and published by Mining Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments
Chrysos signs first PhotonAssay unit contract with Newmont
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...